Azupedia

Sodium/glucose cotransporter 2/ja: Difference between revisions

Sodium/glucose cotransporter 2/ja
← Older edit
VisualWikitext
No edit summary
Tags: Mobile edit Mobile web edit
No edit summary
Tags: Mobile edit Mobile web edit
 
(5 intermediate revisions by the same user not shown)
Line 4: Line 4:
'''ナトリウム/グルコース共輸送体2'''（'''sodium/glucose cotransporter 2'''）（SGLT2）は、ヒトでは{{gene|SLC5A2}}によってコードされる[[protein/ja|タンパク質]]である。
'''ナトリウム/グルコース共輸送体2'''（'''sodium/glucose cotransporter 2'''）（SGLT2）は、ヒトでは{{gene|SLC5A2}}によってコードされる[[protein/ja|タンパク質]]である。


<div lang="en" dir="ltr" class="mw-content-ltr">
== 機能 ==
== Function ==
{{Anchor|Function}}
SGLT2 is a member of the [[sodium-glucose transport proteins|sodium glucose cotransporter family]], which are sodium-dependent [[glucose]] transport proteins. SGLT2 is the major cotransporter involved in glucose [[reabsorption]] in the kidney.  SGLT2 is located in the early [[proximal tubule]], and is responsible for reabsorption of 80-90% of the glucose filtered by the kidney [[Glomerulus (kidney)|glomerulus]]. Most of the remaining glucose absorption is by [[sodium/glucose cotransporter 1]] (SGLT1) in more distal sections of the proximal tubule.
SGLT2は、ナトリウム依存性[[glucose/ja|グルコース]]輸送タンパク質である[[sodium-glucose transport proteins/ja|ナトリウムグルコース共輸送体ファミリー]]のメンバーである。SGLT2は、腎臓におけるグルコースの[[reabsorption/ja|再吸収]]に関与する主要な共輸送体である。 SGLT2は初期の[[proximal tubule/ja|近位尿細管]]に存在し、腎臓[[Glomerulus (kidney)/ja|糸球体]]で濾過されるグルコースの80～90％の再吸収を担っている。残りのグルコース吸収のほとんどは、近位尿細管のより遠位部にある[[sodium/glucose cotransporter 1/ja|ナトリウム/グルコース共輸送体1]]（SGLT1）によるものである。
</div>


<div lang="en" dir="ltr" class="mw-content-ltr">
== 糖尿病治療薬SGLT2阻害薬 ==
== SGLT2 inhibitors for diabetes ==
{{Anchor|SGLT2 inhibitors for diabetes}}
{{Main|SGLT2 inhibitor}}
{{Main/ja|SGLT2 inhibitor/ja}}
[[SGLT2 inhibitor]]s are also called gliflozins or flozins. They lead to a reduction in blood glucose levels, and therefore have potential use in the treatment of [[type 2 diabetes]]. Gliflozins enhance glycemic control as well as reduce [[Human body weight|body weight]] and systolic and diastolic [[blood pressure]]. The gliflozins canagliflozin, dapagliflozin, and empagliflozin may lead to euglycemic [[ketoacidosis]]. Other side effects of gliflozins include increased risk of Fournier gangrene
[[SGLT2 inhibitor/ja|SGLT2阻害薬]]は、グリフロジンまたはフロジンとも呼ばれる。SGLT2阻害薬は血糖値を低下させるため、[[type 2 diabetes/ja|2型糖尿病]]の治療に使用される可能性がある。グリフロジンは血糖コントロールを高めるだけでなく、[[Human body weight/ja|体重]]や収縮期および拡張期[[blood pressure/ja|血圧]]を低下させる。グリフロジンのカナグリフロジン、ダパグリフロジン、エンパグリフロジンは、優血[[ketoacidosis/ja|ケトアシドーシス]]を引き起こす可能性がある。グリフロジンのその他の副作用には、フルニエ壊疽のリスク増大が含まれる
</div>


<div lang="en" dir="ltr" class="mw-content-ltr">
== 臨床的意義 ==
== Clinical significance ==
{{Anchor|Clinical significance}}
</div>


<div lang="en" dir="ltr" class="mw-content-ltr">
この遺伝子の変異は[[renal glycosuria/ja|腎性糖尿症]]とも関連している。
Mutations in this gene are also associated with [[renal glycosuria]].
</div>


<div lang="en" dir="ltr" class="mw-content-ltr">
== こちらも参照 ==
== See also ==
* [[SGLT/ja|SGLT]]ファミリー
* [[SGLT]] Family
* [[Discovery and development of gliflozins/ja|グリフロジンの発見と開発]]
* [[Discovery and development of gliflozins]]
* [[Phlorizin/ja|フロリジン]] — [[SLC5A1/ja|SGLT1]]および[[SGLT2/ja|SGLT2]]の競合的阻害薬である。
* [[Phlorizin]] — a competitive inhibitor of [[SLC5A1|SGLT1]] and [[SGLT2]]
</div>


<div lang="en" dir="ltr" class="mw-content-ltr">
== References ==
== References ==
{{reflist|33em}}
{{reflist|33em}}
</div>


<div lang="en" dir="ltr" class="mw-content-ltr">
== さらに読む ==
== Further reading ==
{{refbegin|33em}}
{{refbegin|33em}}
* {{cite journal | vauthors = van den Heuvel LP, Assink K, Willemsen M, Monnens L | title = Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2) | journal = Human Genetics | volume = 111 | issue = 6 | pages = 544–7 | date = Dec 2002 | pmid = 12436245 | doi = 10.1007/s00439-002-0820-5 | s2cid = 28089635 }}
* {{cite journal | vauthors = van den Heuvel LP, Assink K, Willemsen M, Monnens L | title = Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2) | journal = Human Genetics | volume = 111 | issue = 6 | pages = 544–7 | date = Dec 2002 | pmid = 12436245 | doi = 10.1007/s00439-002-0820-5 | s2cid = 28089635 }}
Line 46: Line 36:
* {{cite journal | vauthors = Castaneda F, Burse A, Boland W, Kinne RK | title = Thioglycosides as inhibitors of hSGLT1 and hSGLT2: potential therapeutic agents for the control of hyperglycemia in diabetes | journal = International Journal of Medical Sciences | volume = 4 | issue = 3 | pages = 131–9 | year = 2007 | pmid = 17505558 | pmc = 1868657 | doi = 10.7150/ijms.4.131 }}
* {{cite journal | vauthors = Castaneda F, Burse A, Boland W, Kinne RK | title = Thioglycosides as inhibitors of hSGLT1 and hSGLT2: potential therapeutic agents for the control of hyperglycemia in diabetes | journal = International Journal of Medical Sciences | volume = 4 | issue = 3 | pages = 131–9 | year = 2007 | pmid = 17505558 | pmc = 1868657 | doi = 10.7150/ijms.4.131 }}
{{refend}}
{{refend}}
</div>


<div lang="en" dir="ltr" class="mw-content-ltr">
{{Solute carrier family/ja|bg|bg0}}
{{Solute carrier family|bg|bg0}}
{{Sodium-glucose transporter modulators/ja}}
{{Sodium-glucose transporter modulators}}
{{二次利用|date=18 December 2023}}
</div>


<div lang="en" dir="ltr" class="mw-content-ltr">
[[Category:Solute carrier family]]
[[Category:Solute carrier family]]
[[Category:Genes mutated in mice]]
[[Category:Genes mutated in mice]]
</div>
Retrieved from "https://wiki.tiffa.net/wiki/Sodium/glucose_cotransporter_2/ja"